Anixa Biosciences (ANIX) Receivables (2012 - 2026)
Anixa Biosciences' (ANIX) quarterly Receivables came in at $56000.0 in Q2 2026, down 67.63% on a QoQ basis from $173000.0 in Q4 2024.
Anixa Biosciences (ANIX) Receivables (2012 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 12 years of Receivables data on file, last reported at $56000.0 in Q2 2026.
- Quarterly Receivables changed N/A year-over-year to $56000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $56000.0 (changed N/A YoY) and the FY2024 annual result came in at $173000.0, down 35.93% from the prior year.
- Receivables retreated to $56000.0 in Q2 2026, from $173000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $410000.0 in Q3 2024 to a low of $46000.0 in Q4 2022.
- A 4-year average of $230100.0 and a median of $237000.0 in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables jumped 486.96% — and 2024, when it plunged 35.93%.
- Tracing ANIX's Receivables over 4 years: stood at $46000.0 in 2022, then jumped by 486.96% to $270000.0 in 2023, then sank by 35.93% to $173000.0 in 2024, then slumped by 67.63% to $56000.0 in 2026.
- The last three Receivables figures came in at $56000.0 (Q2 2026), $173000.0 (Q4 2024), and $410000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Anixa Biosciences | 122.61 Mn | 122.61 Mn | - | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 56,000.00 |
| Oct 31, 2024 | 173,000.00 |
| Jul 31, 2024 | 410,000.00 |
| Apr 30, 2024 | 218,000.00 |
| Jan 31, 2024 | 391,000.00 |
| Oct 31, 2023 | 270,000.00 |
| Jul 31, 2023 | 334,000.00 |
| Apr 30, 2023 | 256,000.00 |
| Jan 31, 2023 | 147,000.00 |
| Oct 31, 2022 | 46,000.00 |
| Oct 31, 2020 | 2,231.00 |
| Jul 31, 2020 | 5,950.00 |
| Apr 30, 2020 | 32,338.00 |
| Jan 31, 2020 | 22,311.00 |
| Oct 31, 2019 | 66,527.00 |
| Jul 31, 2019 | 1,072.00 |
| Apr 30, 2019 | 796,954.00 |
| Oct 31, 2018 | 306,991.00 |
| Jul 31, 2017 | 221,049.00 |
| Jan 31, 2015 | 45,000.00 |